Atop a growing body of research that examines how rheumatoid arthritis (RA) symptoms are dictated by the body’s circadian rhythms, a recent study seems to explain why so many people-RA sufferers included-wake up each day with stiff joints.
Interleukin-1β (IL-1beta), a cytokine that plays in important role in the body’s immune response, turns out to be part of the body’s early defense system for bacterial infections. Anti-inflammation treatments for autoimmune conditions like rheumatoid arthritis (RA) often times inhibit IL-1beta to mitigate the inflammation that it initiates when infection is detected.
The blistering pace of mobile innovation has opened countless doors for clinical application. Built on Apple's ResearchKit platform, GSK's PARADE app seeks to study rheumatoid arthritis patients in their daily lives.
Patients with psoriasis, psoriatic arthritis, and rheumatoid arthritis still face challenges research has yet to meet, according to the authors: “Given the commonality of comorbidities across all three diseases, there is a degree of overlap in their management.”
Professor Aida Babaeva compared cardiovascular effects of immunotherapy plus standard treatments to those evident with the standard treatment alone, claiming the anticytokines doubled chances of reaching target blood pressure and more than halved risk of cardiovascular events.
A new study finds electronic stimulation from implantable bioelectronic devices capable of reducing production of inflammatory agents in rheumatoid arthritis sufferers, a finding its authors consider groundbreaking.